Joinn Laboratories (06127) has accumulated repurchased 3.2698 million A shares by the end of February.
Zhao Yan Pharmaceutical (06127) announced that in February 2025, the company did not repurchase A-shares. As of 2025...
Joinn Laboratories (06127) announced that in February 2025, the company did not repurchase any A shares. As of February 28, 2025, the company has repurchased a total of 3.2698 million A shares through centralized bidding, accounting for 0.4363% of the total shares on the announcement date. The highest repurchase price was RMB 18.15 per share, and the lowest repurchase price was RMB 13.20 per share, with a total fund used of RMB 52.9918 million (excluding transaction costs).
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
